. 2021 Nov 18;8(1):e215445. doi: 10.1001/jamaoncol.2021.5445

Table 2. Chronic Toxicity at 12 and 36 Months After Completion of Treatment.

Variable	Patients, No. (%)
	Toxicity at 12 mo				Toxicity at 36 mo^a
	TNT group A (n = 117)		TNT group B (n = 109)		TNT group A (n = 85)		TNT group B (n = 66)
	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4
Total	72 (61.5)	18 (15.4)	67 (61.5)	19 (17.4)	43 (50.6)	10 (11.8)	52 (64.2)	8 (9.9)
Gastrointestinal
Anastomotic stenosis	3 (4.8)	1 (1.6)	1 (1.5)	0	2 (3.5)	0	2 (3.3)	0
Diarrhea	23 (36.5)	0	29 (43.9)	1 (1.5)	18 (31.6)	2 (3.5)	26 (42.6)	3 (4.9)
Proctitis	4 (6.3)	0	4 (6.1)	0	4 (4.7)	1 (1.8)	3 (4.9)	2 (3.3)
Rectal pain	5 (7.9)	0	1 (1.5)	0	2 (3.5)	0	1 (1.6)	0
Intestinal stoma site bleeding	0	0	0	0	0	1 (1.2)	0	0
Intestinal stoma prolapse	1 (0.9)	1 (0.9)	1 (0.9)	0	0	1 (1.2)	0	0
Genitourinary
Voiding disorder	5 (4.3)	0	5 (4.6)	1 (0.9)	3 (3.5)	0	1 (1.2)	0
Cystitis	2 (1.7)	0	5 (4.6)	0	2 (2.4)	0	1 (1.2)	0
Erectile dysfunction	6 (7.5)	2 (2.5)	12 (15.6)	2 (2.6)	5 (8.8)	2 (3.5)	11 (20.4)	1 (1.9)
Vaginal dryness	0	0	2 (6.2)	1 (3.1)	0	0	0	0
Neurologic
Sensory neuropathy	30 (25.6)	0	26 (23.9)	2 (1.8)	15 (17.6)	1 (1.2)	22 (27.2)	0
Oxaliplatin neurotoxicity (according to Wasserman score)	33 (28.2)	11 (9.4)^b	24 (22.0)	10 (9.2)^c	14 (16.5)	1 (1.2)	19 (23.5)	2 (2.5)
Fistula
Rectovesical	0	1 (0.9)	0	0	0	0	0	0
Rectovaginal	0	0	0	1 (3.1)		0	0	0
Other
Radiation dermatitis	3 (2.6)	0	3 (2.8)	0	2 (2.4)	0	0	0
Various	35 (29.9)	5 (4.3)	21 (19.3)	4 (3.7)	9 (10.6)	3 (3.5)	7 (8.6)	2 (2.5)

Abbreviation: TNT, total neoadjuvant therapy.

^{^a}

No grade 4 toxicity was documented in any of the 2 groups at 36 months.

^{^b}

Only 1 of the 11 patients in group A developed grade 4 neurotoxicity per Wasserman score at 12 months; the remaining patients had grade 3 neurotoxicity.

^{^c}

None of the 10 patients in group B had grade 4 neurotoxicity per Wasserman score at 12 months.